We are live on ! Find out more

Evolus

EOLS

Market cap $518M

7.84 USD

-0.07

0.88%

At close Updated Sep 11, 4:00 PM EDT

Pre-market

After hours

7.81

-0.03

0.38%

1 day

-0.88%

5 days

-13.37%

1 month

-6%

3 months

20.43%

6 months

45.45%

Year to date

16.67%

1 year

4.39%

5 years

-3.09%

10 years

-31.83%

About: Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.

Employees: 353

Healthcare Drug Manufacturers - Specialty & Generic

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 36.4%

Neutral 63.6%

Negative 0%

Zacks Investment Research

Wall Street Analysts Think Evolus (EOLS) Could Surge 77.68%: Read This Before Placing a Bet

The mean of analysts' price targets for Evolus (EOLS) points to a 77.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Evolus (EOLS) Could Surge 77.68%: Read This Before Placing a Bet

Zacks Investment Research

Wall Street Analysts Believe Evolus (EOLS) Could Rally 106.08%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 106.1% in Evolus (EOLS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Evolus (EOLS) Could Rally 106.08%: Here's is How to Trade

Evolus: The Injectable Platform Is Becoming The Real Moat

Evolus is evolving into a multi-product aesthetics platform, leveraging its distribution network and loyalty ecosystem to drive operating leverage and recurring revenue. Q2 2026 results showed 21% revenue growth, positive adjusted EBITDA, and raised guidance, with management projecting 2028 revenue of $450M–$500M and EBITDA margins of 13–15%. Evolus trades at a forward EV/Sales of 1.86, a 50% discount to sector median, but requires margin expansion to justify valuation as it transitions from single-product to platform economics.

Evolus: The Injectable Platform Is Becoming The Real Moat

Evolus, Inc. (EOLS) Q2 2026 Earnings Call Transcript

Evolus, Inc. (EOLS) Q2 2026 Earnings Call Transcript

Evolus, Inc. (EOLS) Q2 2026 Earnings Call Transcript

Zacks Investment Research

Evolus, Inc. (EOLS) Reports Break-Even Earnings for Q2

Evolus, Inc. (EOLS) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.24 per share a year ago.

Evolus, Inc. (EOLS) Reports Break-Even Earnings for Q2

Evolus Q2 Earnings Call Highlights

Evolus NASDAQ: EOLS reported second-quarter revenue growth of 21% and raised the lower end of its full-year 2026 revenue outlook, citing market-share gains in neurotoxins and hyaluronic acid injectable gels, continued customer adoption of its portfolio and expanding international operations.

Evolus Q2 Earnings Call Highlights

Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financial results for the second quarter ended June 30, 2026. “The increasing momentum of our portfolio focus has resulted in Evolus gaining significant share across injectable aesthetics during the second quarter, supported by double-digit growth for Jeuveau® and accelerating adoption of Evolysse®,” said.

Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook

Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has expanded its partnership with Symatese through an amendment to the companies' existing licensing and distribution agreement, providing Evolus with the exclusive rights to commercialize the Estyme® (pronounced “esteem”) collection of injectable hyaluronic acid (HA) gels in Canada, Australia, and New Zea.

Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand

Evolus to Report Second Quarter Financial Results on August 5, 2026

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its second quarter 2026 financial results on Wednesday, August 5, 2026, after the U.S. financial markets close.Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks.To pa.

Evolus to Report Second Quarter Financial Results on August 5, 2026

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant during April 2026 to July 2026 of an aggregate of 115,000 restricted stock units (RSUs) of the company's common stock to 38 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus' 2023 Inducement Incentiv.

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

See News Rankings

Price charts implemented using Lightweight Charts™